Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Marco Bissig"'
Autor:
Angela Greco, Giovanni Rabito, Michela Pironi, Marco Bissig, Saida Parlato, Laura Andreocchi, Giorgia Bianchi, Marilù Poretti Guigli, Michael Llamas, Rita Monotti, Leander Sciolli, Franco Ravetta, Roberto Della Bruna, Anna Zasa, Daniela Stehrenberger, Olivier Giannini, Luca Gabutti
Publikováno v:
Swiss Medical Weekly, Vol 146, Iss 2526 (2016)
QUESTIONS UNDER STUDY: Hypokalaemia in inpatients is common, and is associated with morbidity and mortality. Its management is risky and not always effective. We launched an educational programme with the aim of increasing the rate of potassium norma
Externí odkaz:
https://doaj.org/article/d303702e276f452789f1cbdafb22c44c
Publikováno v:
Future Oncology. 14:2403-2414
Biologic therapies target aberrant pathways in diseases including diabetes, cancer and autoimmune disorders. Despite recent scientific advances, patient access to these agents can be limited. Biosimilars are designed to be highly similar to the origi
Autor:
Josefien Knoeff, Jean-Daniel Hecq, Marco Bissig, Daan J.A. Crommelin, Stefan Mühlebach, Alberto Morell-Baladrón, Hans-Peter Lipp, Alain Astier, Amy Barton Pai, Beat Flühmann
Publikováno v:
Annals of the New York Academy of Sciences. 1407:50-62
Nanomedicines in the class of nonbiological complex drugs (NBCDs) are becoming increasingly available. Up to 23 nanomedicines have been approved, and approximately 50 are in clinical development. Meanwhile, the first nanosimilars have entered the mar
Publikováno v:
Br J Clin Pharmacol
Autor:
Alain, Astier, Amy, Barton Pai, Marco, Bissig, Daan J A, Crommelin, Beat, Flühmann, Jean-Daniel, Hecq, Josefien, Knoeff, Hans-Peter, Lipp, Alberto, Morell-Baladrón, Stefan, Mühlebach
Publikováno v:
Annals of the New York Academy of Sciences. 1407(1)
Nanomedicines in the class of nonbiological complex drugs (NBCDs) are becoming increasingly available. Up to 23 nanomedicines have been approved, and approximately 50 are in clinical development. Meanwhile, the first nanosimilars have entered the mar
Autor:
Loriana, Di Giammarino, Florian, Bihl, Marco, Bissig, Beatrice, Bernasconi, Andreas, Cerny, Enos, Bernasconi
Publikováno v:
Swiss medical weekly. 135(47-48)
The use of guidelines standardises prescription practices for antibiotics against the most common infectious diseases (ID) and favours an early switch from intravenous (IV), to oral (PO) therapy. The goals of this observational study were to evaluate
Autor:
Daan, Crommelin, Theresa, Bermejo, Marco, Bissig, Jaak, Damiaans, Irene, Krämer, Patrick, Rambourg, Giovanna, Scroccaro, Borut, Strukelj, Roger, Tredree, Claudio, Ronco
Publikováno v:
Contributions to nephrology. 149
This contribution describes the present regulatory status in the EU of biosimilars, the generic versions of the first generation of therapeutic proteins. It points out why and where recombinant protein molecules and low-molecular-weight drugs differ
Autor:
Borut Strukelj, Patrick Rambourg, Roger Tredree, Giovanna Scroccaro, Theresa Bermejo, Claudio Ronco, Irene Krämer, Jaak Damiaans, Marco Bissig, Daan J.A. Crommelin
This contribution describes the present regulatory status in the EU of biosimilars, the generic versions of the first generation of therapeutic proteins. It points out why and where recombinant prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::563634315fa0497aedb917f2aa2d93b0
https://doi.org/10.1159/000085690
https://doi.org/10.1159/000085690